Clinical Trials Browser

Interventional × Chromosome Aberrations × Daunorubicin × Clear all

NCT02403310 2022-10-03

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Phase 1 Completed

Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Leukemia, Myeloid, Acute